A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation

Trials

Volumn 11, Issue , 2010, Pages

  Haidinger, Michael ^a   Werzowa, Johannes ^a   Voigt, Hans Christian ^a   Pleiner, Johannes ^a   Stemer, Gunar ^b   Hecking, Manfred ^a   Döller, Dominik ^a   Hörl, Walter H ^a   Weichhart, Thomas ^a   Säemann, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PLACEBO; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; NITRILE; PYRROLIDINE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY TRANSPLANTATION; ORAL GLUCOSE TOLERANCE TEST; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; AUSTRIA; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL PROTOCOL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIA; METABOLISM; METHODOLOGY; PLACEBO EFFECT; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADAMANTANE; AUSTRIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CLINICAL PROTOCOLS; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY TRANSPLANTATION; NITRILES; PLACEBO EFFECT; PROSPECTIVE STUDIES; PYRROLIDINES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957307704     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-91     Document Type: Article

References (20)

1. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000, 57:307-13. 10.1046/j.1523-1755.2000.00816.x, 10620213.
2. Kendrick E. Cardiovascular disease and the renal transplant recipient. Am J Kidney Dis 2001, 38:S36-43. 10.1053/ajkd.2001.28924, 11729004.
3. Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009, 52:2001-14. 10.1007/s00125-009-1454-0, 2744770, 19629430.
4. Davidson JA, Wilkinson A. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care 2004, 27:805-12. 10.2337/diacare.27.3.805, 14988309.
5. Bodziak KA, Hricik DE. New-onset diabetes mellitus after solid organ transplantation. Transpl Int 2009, 22:519-30. 10.1111/j.1432-2277.2008.00800.x, 19040489.
6. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002, 25:583-92. 10.2337/diacare.25.3.583, 11874952.
7. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005, 19:291-8. 10.1111/j.1399-0012.2005.00359.x, 15877787.
8. Rodrigo E, Fernandez-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol 2006, 17:S291-5. 10.1681/ASN.2006080929, 17130277.
9. Balla A, Chobanian M. New-onset diabetes after transplantation: a review of recent literature. Curr Opin Organ Transplant 2009, 14:375-9. 10.1097/MOT.0b013e32832dbb98, 19542891.
10. Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG. Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?. Scand J Urol Nephrol Suppl 1980, 54:135-8.
11. Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens 2009, 18:404-11. 10.1097/MNH.0b013e32832edcb2, 19593130.
12. Doupis J, Veves A. DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther 2008, 25:627-43. 10.1007/s12325-008-0076-1, 18641927.
13. Mathieu C, Degrande E. Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vasc Health Risk Manag 2008, 4:1349-60. 2663430, 19337548.
14. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009, 297:127-36. 10.1016/j.mce.2008.08.012, 18786605.
15. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25:435-41. 10.1111/j.1464-5491.2008.02391.x, 18341596.
16. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:2078-84. 10.1210/jc.2003-031907, 15126524.
17. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007, 9:166-74. 10.1111/j.1463-1326.2006.00684.x, 17300592.
18. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007, 39:218-23. 10.1055/s-2007-970422, 17373638.
19. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-8. 10.1016/j.diabres.2006.12.009, 17223217.
20. Thuren TBS, Mohideen P, Goodman M. Vildagliptin is Safe and Well Tolerated in Patients with Mild or Moderate Renal Impairment. In The 44th Annual Meeting of the European Association for the Study of Diabetes 2008,